Fluorinated dihydrotetrabenazine ether imaging agents and probes
US7897770B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2007 |
| Grant date | Mar 1, 2011 |
| Priority date | — |
| Expiry date | Nov 4, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K51/0455
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides novel fluorinated ether compounds having structure Iwherein R1 is a C2-C10 fluorinated aliphatic radical; R2 is a C1-C10 aliphatic radical, or a C3-C10 cycloaliphatic radical; R3 is hydrogen or a C1-C10 aliphatic radical; and R4 is hydrogen or a C1-C10 aliphatic radical. The fluorinated ether compounds are provided in both racemic and enantiomerically enriched forms and may comprise either or both of fluorine-18 and fluorine 19. The fluorinated ether compounds are shown to possess high affinity for VMAT-2, a biomarker implicated in human diabetes. The fluorinated ether compounds comprising a fluorine-18 group are useful as PET imaging agents targeting the VMAT-2 biomarker. The non-radiolabeled fluorinated ether compounds are useful as probes for the discovery of PET imaging agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.